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Abstract
A common feature of human and veterinary pharmacokinetics is the importance of identifying and
quantifying the key determinants of between-patient variability in drug disposition and effects. Some of these
attributes are already well known to the field of human pharmacology such as bodyweight, age, or sex, while
others are more specific to veterinary medicine, such as species, breed, and social behavior. Identification of
these attributes has the potential to allow a better and more tailored use of therapeutic drugs both in
companion and food-producing animals. Nonlinear mixed effects (NLME) have been purposely designed to
characterize the sources of variability in drug disposition and response. The NLME approach can be used to
explore the impact of population-associated variables on the relationship between drug administration,
systemic exposure, and the levels of drug residues in tissues. The latter, while different from the method used
by the US Food and Drug Administration for setting official withdrawal times (WT) can also be beneficial for
estimating WT of approved animal drug products when used in an extralabel manner. Finally, NLME can also
prove useful to optimize dosing schedules, or to analyze sparse data collected in situations where intensive
blood collection is technically challenging, as in small animal species presenting limited blood volume such as
poultry and fish.
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A	common	feature	of	human	and	veterinary	pharmacokinetics	 is	 the	 importance	of	
identifying	 and	 quantifying	 the	 key	 determinants	 of	 between-	patient	 variability	 in	
drug	disposition	and	effects.	Some	of	these	attributes	are	already	well	known	to	the	
field	of	human	pharmacology	such	as	bodyweight,	age,	or	sex,	while	others	are	more	
specific	 to	 veterinary	 medicine,	 such	 as	 species,	 breed,	 and	 social	 behavior.	
Identification	of	these	attributes	has	the	potential	to	allow	a	better	and	more	tailored	
use	of	therapeutic	drugs	both	 in	companion	and	food-	producing	animals.	Nonlinear	
mixed	effects	 (NLME)	have	been	purposely	designed	to	characterize	the	sources	of	
variability	in	drug	disposition	and	response.	The	NLME	approach	can	be	used	to	ex-
plore	the	impact	of	population-	associated	variables	on	the	relationship	between	drug	
administration,	systemic	exposure,	and	the	levels	of	drug	residues	in	tissues.	The	lat-
ter,	while	different	from	the	method	used	by	the	US	Food	and	Drug	Administration	for	
setting	official	withdrawal	times	(WT)	can	also	be	beneficial	for	estimating	WT	of	ap-
proved	animal	drug	products	when	used	in	an	extralabel	manner.	Finally,	NLME	can	
also	prove	useful	to	optimize	dosing	schedules,	or	to	analyze	sparse	data	collected	in	
situations	where	intensive	blood	collection	is	technically	challenging,	as	in	small	animal	
species	presenting	limited	blood	volume	such	as	poultry	and	fish.
2  |     BON et al.
1  | INTRODUCTION
The	primary	objective	of	population	pharmacokinetics	 (PK)	and	PK/
pharmacodynamic	 (PD)	 studies	 is	 to	 help	 veterinary	 care	 providers	
understand	the	impact	of	factors	(covariates)	such	as	age,	sex,	breed,	
and	 disease	 on	 the	 drug	 dose–exposure–response	 (Lees,	 Landoni,	
Giraudel,	&	Toutain,	2004).	As	in	human	medicine,	there	is	a	need	to	
identify	the	key	variables	that	influence	drug	disposition	and	response,	
and	to	quantify	the	magnitude	of	their	effects	 in	veterinary	species.	
In	addition,	the	very	nature	of	collective	mass	treatment	in	large	an-
imals	 can	 be	 a	 source	 of	variability	 in	 the	 dose–exposure–response	
relationship,	 reflecting	 interactions	 between	 animal	 characteristics	
and	husbandry	practices	(Lees	&	Toutain,	2012).	In	so	doing,	an	appre-
ciation	of	the	sources	of	population	variability	will	support	efforts	to	
optimize	clinical	efficacy,	minimize	safety	risks,	support	dose	and	drug	
selection,	as	well	as	 to	 identify	potential	concerns	 for	safety	and/or	
effectiveness	in	companion	or	food-	producing	animals.
Nonlinear	 mixed-	effects	 (NLME)	 models	 are	 a	 versatile	 tool	 for	
quantifying	 variability	 in	 drug	 disposition	 and	 response	 as	 a	 func-
tion	 of	 significant	 patient	 characteristics	 (i.e.,	 covariates)	 (Sheiner,	
Rosenberg,	&	Melmon,	1972).	NLME	can	be	used	for	analyzing	either	
dense	or	sparse	data,	 including	observations	from	unbalanced	study	
designs	 (FDA/CDER/CBER,	1999).	The	utility	of	NLME	ranges	 from	
the	 analysis	 of	 data	 generated	 in	 preclinical	 studies	 to	 applications	
targeting	 recommendations	 for	 the	 individualization	 of	 dosage	 regi-
mens	(Holford	&	Buclin,	2012;	Liefaard	&	Chen,	2015).	NLME	models	
are	also	being	used	by	advising	groups	such	as	the	Food	Animal	Drug	
Residue	Avoidance	Databank	 (FARAD)	 to	provide	 a	 robust	 estimate	
of	the	withdrawal	time	for	edible	tissues	in	situations	when	a	drug	or	
drug	product	has	been	used	in	an	extralabel	manner	(i.e.,	using	a	route,	
dosage,	frequency,	or	in	species	other	than	that	indicated	on	the	ap-
proved	drug	product	label).
The	Animal	Health	Modeling	&	Simulation	(AHM&S)	Society	was	
founded	in	2012	to	create	an	international	forum	promoting	the	use	
of	 in	 silico	 tools	 to	 support	 veterinary	 drug	 development	 (Mochel,	
Gabrielsson	et	al.,	2013).	This	review	article	is	part	of	a	series	of	white	
papers	designed	to	illustrate	the	value	and	applications	of	mathemat-
ical	models	in	veterinary	pharmacology	and	toxicology.	In	previous	re-
views,	an	introduction	to	modeling	and	simulation	(Riviere,	Gabrielsson,	
Fink,	 &	 Mochel,	 2016),	 and	 the	 principles	 of	 physiologically	 based	
pharmacokinetics	 (Lin,	Gehring,	Mochel,	Lave,	&	Riviere,	2016)	have	
been	presented.	The	focus	of	this	study	was	on	the	concept,	definition,	
and	application	of	NLME	models	in	veterinary	sciences.
2  | MOTIVATION AND RATIONALE FOR 
USING NLME
The	 statistical	methodology	 that	 supports	NLME	was	 described	 by	
Lewis	Sheiner	in	a	seminal	paper	entitled	“Modelling of individual phar-
macokinetics for computer-aided drug dosage”	 (Sheiner	 et	al.,	 1972).	
Sheiner	proposed	a	quantitative	approach	for	analyzing	sparse	clinical	
data	and	recognized	that	the	relationship	between	observed	data	and	
model	parameters	was	nonlinear	by	nature.	Therapeutic	drug	moni-
toring	for	individualized	digoxin	dosing	in	heart	disease	patients	later	
crystallized	 the	 first	human	clinical	 application	of	NLME	by	Sheiner	
in	the	early	1970s	(Peck,	Sheiner,	Martin,	Combs,	&	Melmon,	1973;	
Sheiner,	 Halkin,	 Peck,	 Rosenberg,	 &	Melmon,	 1975).	 Subsequently,	
Sheiner	 and	 Beal	 (1983)	 contributed	 to	 the	 dissemination	 of	 the	
NLME	approach	by	developing	 the	 computer	 software	NONMEM® 
(nonlinear	mixed-	effect	modeling,	ICON	Development	Solutions),	pro-
viding	a	unique	analytical	platform	for	pharmacokineticists	(Mould	&	
Upton,	2012).
Prior	 to	 the	 availability	 of	 the	 NLME	 approach,	 population	 pa-
rameters	were	expressed	as	either	means	or	medians	based	upon	a	
pooling	of	individual	data	into	a	single	concentration–time	course	(i.e.,	
the	 naïve	 pooling	 approach,	which	 largely	 ignores	 between-	subject	
differences),	or	by	fitting	a	model	to	individual	concentrations	vs.	time	
profiles,	and	subsequently	generating	average	parameter	values	 (the	
so-	called	“two-	stage	approach”).	However,	as	summarized	by	Mould	
and	Upton	(Mould	&	Upton,	2012),	both	methods	have	inherent	prob-
lems	that	are	magnified	in	the	presence	of	dosing	noncompliance	or	
missing	data,	potentially	resulting	in	biased	population	estimates.
Alternatively,	NLME	models	have	the	ability	to	leverage	informa-
tion:	(i)	using	data	from	informative	subjects	(e.g.,	individuals	present-
ing	a	rich	and	consistent	pharmacokinetic	time	course,	with	only	few	
“aberrant”	data	points)	to	estimate	model	parameters	from	apparent	
“outliers,”	while	 (ii)	simultaneously	considering	drug	effect	and	base-
line	 and	 (iii)	 identifying	 relevant	 covariates	 that	 significantly	 affect	
drug	 disposition	 and/or	 response	 (Mochel	 &	Danhof,	 2015).	 NLME	
models	can	also	be	used	to	combine	data	from	individual	plasma	and	
tissue	PK	experiments,	or	to	conduct	meta-	analyses	across	published	
studies	(Li,	Gehring,	Lin,	&	Riviere,	2015;	Li	et	al.,	2014;	Ogungbenro	
&	Aarons,	2014;	Rey	et	al.,	 2014).	While	mixed-	effects	models	 effi-
ciently	function	with	only	three	or	four	samples	per	individual,	a	larger	
size	 of	 the	 target	 population	 is	 often	 required	 as	 compared	 to	 the	
naïve	or	two-	stage	approach.
To	date,	NLME	models	have	been	underutilized	in	veterinary	sci-
ences.	However,	 and	 as	discussed	below,	 they	 can	provide	 a	 highly	
efficient	method	 for	 addressing	 some	 of	 the	 unique	 challenges	 en-
countered	in	veterinary	medicine.
3  | VARIABILITY IS NOT NOISE
Between-	individual	variability	is	often	perceived	as	noise	that	should	
be	controlled	through	complex	study	designs	and	restrictive	inclusion	
criteria	 (Ette	 &	 Williams,	 2004).	 However,	 from	 a	 population	 per-
spective,	this	variability	is	in	fact	relevant	biological	information	that	
should	be	quantified	and	not	ignored.	In	essence,	between-	individual	
variability	comprises	predictable and random	(i.e.,	not	explained)	vari-
ance	 components.	 The	predictable	 component	 can	be	 explained	by	
covariates	(i.e.,	by	population	characteristics,	or	external	determinants	
such	as	husbandry	or	 clinical	practices).	 In	human	medicine,	 covari-
ates	 typically	 comprise	 constitutional	 factors	 (e.g.,	 bodyweight,	 age,	
genotype),	and	physiological	parameters	 (e.g.,	markers	of	renal	and/
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or	hepatic	 function).	 In	veterinary	medicine,	 additional	 factors	need	
to	be	considered,	such	as	hierarchy	in	pigs	(Soraci,	Amanto,	Tapia,	de	
la	Torre,	&	Toutain,	2014),	which	influences	the	ingested	amount	of	
drug	 in	medicated	 feeds,	or	social	behavior	manifested	by	allo-	and	
hetero-	licking	described	in	cattle,	which	is	known	to	affect	the	drug	
disposition	 of	 pour-	on	 formulations	 (Toutain,	 Modric,	 Bousquet-	
Mélou,	Sallovitz,	&	Lanusse,	2012).	An	overview	of	potential	sources	
of	variability	in	drug	disposition	kinetics	in	veterinary	medicine	is	pre-
sented	in	Table	1.
In	contrast	 to	variability,	sources	of	 random	error	 (i.e.,	 the	resid-
ual	error,	or	noise)	should	be	minimized	to	the	extent	possible.	Noise	
is	 often	 described	 as	 a	 function	 of	 one	 of	 three	 categories:	 (i)	 pre-	
analytical	error,	(ii)	analytical	error,	and	(iii)	postanalytical	error.
Pre-analytical	error	is	related	to	uncertainties	associated	with	pro-
cedures	 carried	 out	 during	 the	 animal	 phase	 (e.g.,	 drug	 administra-
tion,	blood	sampling,	blood	collection	times,	handling	and	processing,	
plasma	storage).
On	 the	 other	 hand,	analytical error	 is	more	 broadly	 associated	
with	 the	uncertainty	of	 the	bioanalytical	 technique	 (e.g.,	 immuno-
assays,	mass	 spectrometry)	 used	 to	 quantify	 drug	 concentrations.	
In	this	regard,	a	source	of	recurrent	uncertainty	in	PK	modeling	per-
tains	to	the	analysis	of	“below	the	limit	of	quantification”	(BLQ)	data	
(Ahn,	Karlsson,	Dunne,	&	Ludden,	2008).	Ignoring	BLQ	data	(referred	
to	as	the	“M1	method”	in	Beal’s	original	paper	[2001])	typically	leads	
to	severe	bias	 in	parameters	estimates,	especially	when	 the	 range	
of	concentrations	of	 interest	 is	 in	the	vicinity	of	the	 lower	 limit	of	
quantification	 (LLOQ),	 as	 is	 the	 case	 in	withdrawal	 time	 determi-
nation	 for	 depletion	 residues	 studies.	This	 form	of	data	 censoring	
results	 in	 the	generation	of	biased	maximum-	likelihood	estimates.	
Censored	data	are	referred	to	as	left-	censored	when	concentrations	
less	 than	 the	 LLOQ	 are	 missing.	 Conversely,	 right-	censoring	 oc-
curs	when	the	high	drug	concentrations	are	ignored.	The	challenge	
imposed	by	right-	censored	data	 is	 that	 there	 is	no	set	upper	 limit,	
making	the	 imputation	process	highly	subjective.	An	alternative	to	
ignoring	BLQ	data	is	to	use	likelihood-	based	principles	for	inferring	
the	 value	 of	 left-	censored	 information	 (“M3	 and	M4	methods”	 in	
Beal’s	description	[2001]).	M3	estimates	the	likelihood	for	measure-
ments	below	the	LLOQ,	but	allows	for	these	values	to	be	negative	
(on	an	assumption	 that	 these	values	 follow	a	normal	distribution).	
M4,	on	the	other	hand,	constrains	the	data	to	values	higher	than	0.	
Bergstrand	 and	Karlsson	 (2009)	 suggested	 an	 alternative	 to	 using	
M4,	using	a	log-	transformation	of	the	dependent	variable	and	then	
applying	the	simpler	M3	approach.	The	authors	found	the	latter	ap-
proach	to	provide	the	least	biased	parameter	predictions.
Another	 issue	 arises	 when	 data	 from	 recent	 pharmacokinetic	
studies	are	merged	together	with	those	from	older	experiments	to	
build	a	single	population	model.	In	fact,	 intrinsic	differences	in	the	
LLOQ,	 accuracy,	 and	 precision	 of	 the	 various	 analytical	 methods	
used	to	derive	 these	data	can	be	a	significant	source	of	analytical	
variability.	This	can	be	handled	by	building	a	residual	error	function	
that	includes	assay	performances	as	a	covariate	in	its	model	struc-
ture	(Bonate,	2011).
Finally,	postanalytical errors	are	those	associated	with	model	mis-
specifications,	reflecting	approximations	made	through	the	mathe-
matical	description	of	the	true	underlying	biology.	Misspecifications	
can	 be	 related	 to	 the	 structural	 model	 itself	 (e.g.,	 use	 of	 a	 one-	
compartment	 instead	 of	 a	 two-	compartment	 model)	 or/and	 to	
the	distribution	of	 the	 random	effects	 (e.g.,	 normal	vs.	 log-	normal	
distribution).
In	addition	to	between-	subject	and	random	variability,	there	is	a	
need	to	recognize	the	potential	impact	of	interoccasion	variability	on	
drug	PK	variance.	This	third	level	of	randomness	may	be	integrated	
with	estimates	of	within-	animal	variability	when	only	a	single	dosing	
event	is	considered.	Alternatively,	in	the	presence	of	repeated	dose	
TABLE  1 Possible	sources	of	variability	in	drug	pharmacokinetics	in	veterinary	medicine
Origin of the variability Reference
Uncertainty	on	dosage
Actual	individual	dose	when	medication	dispensed	for	a	group	in	food	
or	water
Soraci	et	al.	(2014)
Interpatient	variability
Species Riviere	et	al.	(1997)
Age Li	et	al.	(2014)
Bodyweight Fink	et	al.	(2013)	and	Lee	and	Maxwell	(2014)
Breed Uney	and	Tras	(2011)
Social	behavior	(allo-	and	hetero-	licking	in	cattle) Toutain	et	al.	(2012)
Disease Leavens	et	al.	(2014),	Kissell	et	al.	(2015),	Shelver	et	al.	(2016),	Sidhu	
et	al.	(2017)	and	Silber	et	al.	(2010)
Lactation Lin,	Cuneo	et	al.	(2016)	and	Lin,	Gehring	et	al.	(2016)
Interoccasion	variability
Time-	dependent	physiological	changes Lee	et	al.	(2006)	and	Konturek	et	al.	(2011)
Chronobiology Mochel,	Fink	et	al.	(2013)	and	Mochel	et	al.	(2014,	2015)
Loc(ation	(owner’s	home	vs.	veterinary	hospital) Whittem	et	al.	(2000)
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administrations,	fluctuations	in	systemic	exposure	over	time	can	be	
captured	by	including	an	interoccasion	variability	term	in	the	struc-
tural	model	(Kontny	et	al.,	2013;	Kristoffersson,	Friberg,	&	Nyberg,	
2015).	Ignoring	this	“day-	to-	day”	variability	can	lead	to	inflation	of	
the	within-	subject	variability	 term,	which	 is	 lumped	 together	with	
all	 other	 sources	 of	 unexplained	 variability	 (Karlsson	 &	 Sheiner,	
1993).	Although	 the	biology	underlying	 interoccasion	variability	 is	
often	poorly	understood,	physiological	attributes	known	to	exhibit	
circadian	 and	 interoccasion	 fluctuations	 such	 as	 gastrointestinal	
(GI)	pH	can	affect	the	ionization	and	overall	solubility	of	oral	drugs	
(Erkekoglu	&	Baydar,	2012).	Other	factors,	such	as	gastric	emptying	
and	GI	blood	flow,	have	been	shown	to	have	an	impact	on	the	time-	
dependent	difference	of	drug	absorption	(Konturek,	Brzozowski,	&	
Konturek,	 2011;	 Lee	 et	al.,	 2006).	Additionally,	 repeated	dose	 ad-
ministrations	can	be	associated	with	changes	in	drug	first-	pass	and/
or	metabolism	in	the	context	of	(hepatic	and/or	intestinal)	enzyme	
induction	 or	 inhibition.	 Overall,	 these	 changes	 can	 be	 described	
using	time-	dependent	 (e.g.,	cosine	and	sine)	covariate	functions	 in	
the	model	structure.
4  | STATISTICAL DEFINITION AND 
CONCEPTS OF NLME
The	structure	of	the	NLME	model	allows	for	some	parameters	to	be	
fixed	(i.e.,	considered	to	be	constant	within	the	population)	while	oth-
ers	are	considered	to	be	varied	(termed	random	effects).
Random-effect parameters	 are	used	 to	 represent	variability	 in	PK	
parameter	estimates	as	a	result	of	between-	and	within-	individual	vari-
ability.	The	individual	statistical	(or	stochastic)	model	can	be	written	as:
where Yij	 describes	 the	 drug	 concentration	 for	 the	 ith	 individual	 at	
time	 j.	Note	 that	within	 the	 framework	of	 the	NLME	approach,	 the	
error	structure	is	assumed	to	be	parametric.
The	function	f()	refers	to	the	structural	model	while	g()	 is	the	re-
sidual	error	model,	with	φi	being	the	vector	of	 individual	PK	 (or	PD)	
parameters,	σ	the	standard	deviation	of	the	distribution	of	the	residual	
error	model,	 εij	 the	 difference	 between	 the	 observed	 concentration	
and	the	concentration	predicted	by	the	model	for	the	 individual	 i	at	
time	j,	and	tij	the	jth	sampling	time	of	the	ith	individual.
The	random-	effect	parameters	are	modeled	as	follows:
where θ	 is	 the	 vector	 of	 population	 parameters	 (also	 referred	 to	
as	 fixed	 effects),	ηi	 is	 the	 vector	 of	 random	effects,	 assumed	 to	 be	
normally	distributed,	and	characterizing	 the	difference	between	 the	
parameter	value	of	the	 ith	individual	and	the	population	(i.e.,	typical	
value)	θ. Ω	is	the	standard	deviation	of	the	distribution	of	the	ηi cor-
responding	to	the	interindividual	variability	of	the	model	parameter.
Population	models	are	referred	to	as	mixed effects	because	they	in-
clude	both	fixed and random-effects	parameters.	They	are	also	nonlinear 
as	they	do	not	depend	upon	a	linear	relationship	between	the	fixed	and	
the	random	effects,	 for	example,	 f	 is	nonlinear	with	 respect	 to	ηi.	As	
described	in	the	previous	section,	the	sources	of	variation	between	the	
individual	parameters	φi	can	be	further	explained	by	population	charac-
teristics	that	can	be	included	additively	or	proportionally	to	θ. The core 
principles	of	NLME	models	are	further	outlined	in	Figures	1	and	2a,b.
5 | APPLICATIONS IN VETERINARY MEDICINE
Initially,	NLME	modeling	was	developed	in	human	medicine	to	sup-
port	individualized	dosing	of	drugs	with	narrow	therapeutic	indices.	
It	proved	to	be	particularly	useful	 in	the	context	of	 large	 interindi-
vidual	variability,	or	where	drug	PK	could	be	affected	by	the	disease	
process	 or	 the	 drug	 itself	 (Sheiner,	 1985).	 Because	 this	 modeling	
approach	 is	amenable	 to	sparsely	sampled	blood	or	 tissue	samples	
(Sheiner	&	Beal,	1983),	it	was	later	recognized	to	be	of	value	in	veter-
inary	pharmacology	to	explore	the	impact	of	covariates	such	as	age,	
sex,	and	disease	status	on	drug	PK	(Martin-	Jimenez	&	Riviere,	1998).
Over	 the	past	15	years,	 several	 peer-	reviewed	NLME	analyses	 in	
veterinary	pharmacology	have	been	published.	The	most	recent	exam-
ples	include	the	study	of	topiramate	in	epileptic	dogs	(Vuu	et	al.,	2016);	
nonsteroidal	 anti-	inflammatory	 drug	 (NSAIDs)	 in	 dogs	 and	 cats	with	
osteoarthritis	(Cox,	Liao,	Payne-	Johnson,	Zielinski,	&	Stegemann,	2011;	
Fink	 et	al.,	 2013;	 Pelligand,	 Soubret,	 King,	 Elliott,	 &	 Mochel,	 2016;	
Silber	et	al.,	2010);	tobramycin	in	horses	(Haritova,	Bakalov,	Hubenov,	
&	Lashev,	2012);	valnemulin	and	cefquinome	in	pigs	(Zhao	et	al.,	2013,	
2014);	 tulathromycin	 in	 lactating	 goats	 (Lin,	 Cuneo	 et	al.,	 2016;	 Lin,	
Gehring	et	al.,	2016);	and	penicillin	G	in	cattle	and	swine	(Li	et	al.,	2014).
5.1 | In food- producing animals
5.1.1 | Regulatory determination of human food 
safety (HFS)
Determination	of	the	withdrawal	period	is	a	key	component	of	the	HFS	
section	of	a	new	animal	drug	application	to	be	used	in	food-	producing	
(1)Yij= f(Dose,tij,φi)+g(Dose,tij,φi,σ)∗εij εij∼N(0,1)
φi=θ+ηi ηi∼N(0,Ω)
F IGURE  1 Structure	of	a	NLME	(Population)	Model,	including	(i)	a	
structural	model,	(ii)	a	statistical/stochastic	model,	and	(iii)	a	covariate	
model	to	explain	part	of	the	between-	subject	variability.	Figure	
adapted	from	Vučićević	et	al.	(2011)
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animals	(FDA/CVM,	2015).	This	time	period	ensures	that,	at	slaughter	
or	harvesting,	the	residues	levels	in	edible	tissues	or	animal	products	
(e.g.,	meat,	milk,	or	eggs)	are	at	or	below	a	concentration	determined	
to	be	safe	for	human	consumption.	Currently,	the	US	FDA	does	not	
accept	 alternative	 approaches	 to	 those	 described	 in	 FDA	Guidance	
documents	 for	 the	 regulatory	 determination	 of	 withdrawal	 times.	
While	approaches	such	as	NLME	models	may	be	applied	in	situations	
of	extralabel	drug	use	or	for	predicting	violative	residues	in	diseased	
animals	 (see	discussion	below),	such	assessments	 fall	outside	of	 the	
purview	of	the	US	FDA.	Summary	information	on	the	determination	
of	withdrawal	times	in	the	United	States	and	the	European	Union	is	
provided in Table 2.
5.1.2 | Importance of NLME for insuring HFS under 
conditions of extralabel drug use
Several	 NLME	models	 have	 been	 published	 as	 tools	 for	 estimating	
the	time	when	FDA-	approved	marker	residues	deplete	below	the	tol-
erance	 or	 detectable	 levels	 in	 extralabel	 use	 situations.	 This	 is	well	
exemplified	by	a	study	from	Li	et	al.	(2014)	where	the	authors	estab-
lished	a	robust	NLME	model	of	penicillin	for	a	large	and	diverse	popu-
lation	of	food-	producing	animals	(Figure	3).	The	model	was	developed	
using	published	data	from	the	literature	and	validated	by	comparing	
the	concentrations	predicted	by	the	model	with	separate,	both	pub-
lished	and	unpublished	independent	datasets.
Usage	of	 drugs	 approved	 for	major	 species	 in	minor	 species	 re-
quires	 that	 dosage	 regimens	 and	withdrawal	 times	 are	 extrapolated	
between	species.	Allometric	models	of	drug	PK	across	animal	species	
are	usually	 formulated	empirically,	building	equations	 that	 relate	PK	
parameters	 to	 factors	 like	 bodyweight,	 brain	 weight,	 or	 maximum	
lifespan	 (Riviere,	Martin-	Jimenez,	 Sundlof,	 &	Craigmill,	 1997).	 Using	
retrospective	data	from	the	FARAD,	Martin-	Jimenez	and	Riviere	(2001,	
2002)	applied	NLME	for	analyzing	the	disposition	of	gentamicin	and	
oxytetracycline	 across	 several	mammalian	 species.	 In	 these	 studies,	
various	 covariates	were	 incorporated	 into	 NLME	 PK	 models,	 using	
data	 from	six	and	seven	species	 for	oxytetracycline	and	gentamicin,	
respectively.	PK	parameters	were	 found	 to	be	exponentially	 related	
to	bodyweight	for	both	oxytetracycline	and	gentamicin.	Interestingly,	
brain	weight	was	also	found	to	be	a	predictor	of	gentamicin	clearance	
in	the	model.
An	advantage	of	this	approach	is	that	 it	maximizes	the	informa-
tion	 that	can	be	gleaned	 from	 limited	available	data,	and	 facilitates	
the	 estimation	 of	 population	 variability	 by	 combining	 data	 from	
several	sources	(e.g.,	 literature	and	raw	data	from	new	studies).	The	
models	can	be	applied	using	Monte	Carlo	simulations	to	predict	con-
centration–time	profiles	for	theoretical	populations	and	thereby	de-
termine	when	 concentrations	 of	 the	marker	 residue	will	 fall	 below	
target	levels	(tolerance	or	levels	of	detection)	in	target	tissues	or	se-
cretions	(e.g.,	milk)	for	a	specified	percentage	of	the	population	(e.g.,	
95th	percentile).
5.1.3 | Future opportunities
Ultimately,	 the	 question	 is	whether	 or	 not	 there	may	 be	 situations	
in	 which	 the	 level	 of	 uncertainty	 already	 incorporated	 into	 regula-
tory	methods,	which	are	based	upon	data	derived	from	a	sample	of	
healthy	animals,	is	adequate	to	ensure	the	highly	diverse	sets	of	con-
ditions	 that	may	be	encountered	with	 field	use.	For	example,	using	
retrospective	data	analysis,	Whittem	(1999)	applied	NLME	to	evalu-
ate	covariates	that	alter	the	necessary	milk	discard	time	after	dosing	
of	dairy	cattle	with	pirlimycin.	This	first	use	of	NLME	for	food	safety	
evaluation	confirmed	the	important	impact	of	low	milk	production	on	
F IGURE  2  (a)	Nonlinear	mixed-	effects	models	can	be	used	to	predict	the	individual	time	course	of	drug	concentrations.	The	individual	
prediction	(IPRED)	is	a	function	of	a	vector	or	individual	parameters	(φ1),	the	input	dose	and	time.	Differences	between	model	predictions	and	
actual	observations	(Yij)	can	be	quantified	using	a	residual	error	model.	More	information	about	model	parameters	and	nomenclature	can	be	
found	in	the	body	of	the	manuscript.	(b)	Nonlinear	mixed	effects	account	for	variability	and	noise	(i.e.,	residual	error),	and	allow	to	predict	the	
drug	concentration–time	course	for	a	typical	(i.e.,	median)	animal	patient	(PRED),	as	well	as	individual	subjects	(IPRED).	Differences	between	
individual	patients	and	the	typical	prediction	are	driven	by	interindividual	variability,	while	deviations	from	individual	observations	are	due	to	
residual	error
(a) (b)
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TABLE  2 Comparison	of	withdrawal	period	determination	based	upon	the	US	FDA	guidance	versus	EMA	approach
US FDA EMA
Alternative population 
approaches explored by EMA
Subject	population Healthy	animals	representative	of	the	
commercial	breed	and	target	population
Animals	should	be	healthy	and,	preferably,	
should	not	have	been	previously	
medicated.	Study	animals	should	be	
representative	of	the	commercial	breeds	
and	representative	of	the	target	animal	
population	that	will	be	treated
Depending	on	covariates,	WT	
could	be	also	estimated	for	
specific	subpopulations	
(according	to	demography,	
clinical	signs,	production	
variables)
Number	of	sites One The	benefits	and	drawbacks	of	combining	
studies	are	discussed	in	a	general	section	
of	the	“Guideline	on	statistical	principles	
for	clinical	trials	for	veterinary	medicinal	
products	(pharmaceuticals)”	(EMA/
CVMP/EWP/81976/2010)
Could	be	multicentric	(the	center	
would	be	a	discrete	covariate)
Statistics 99%	tolerance	limit	estimate	with	95%	
confidence
Time	when	the	upper	one-	sided	95%	
tolerance	limit	for	the	residue	is	below	the	
MRL	with	95%	confidence
Time	when	the	upper	limit	of	the	
98%	prediction	interval	of	the	
nonlinear	mixed-	effects	model	
is	below	the	MRL	with	95%	
confidence
Target	value Tolerance	(maximum	concentration	of	the	
marker	residue)
Maximum	residue	limit	(MRL) No	change
Moiety	being	
monitored
Marker	residue	(exits	in	a	known	
relationship	to	total	residue)
Marker	residue	is	that	residue	whose	
concentration	is	in	a	known	relationship	
to	the	concentration	of	total	residue	in	an	
edible	tissue
No	change
Tissue Typically	the	slowest	depleting	tissue Typically	the	slowest	depleting	tissue No	change
Objective	of	WT	
determination
Insure	consumer	safety.	Therefore,	
estimates	are	intentionally	conservative
Ensure	consumer	safety NLME	modeling	has	many	
advantages	that	can	help	
optimizing	the	information	
required	to	ensure	consumer	
safety	(but	also	to	reduce	costs	
for	marketing	authorization	
holders)
Conclusion If	marker	residue	is	at	or	below	tolerance,	
then	the	edible	tissues	will	have	a	
concentration	of	total	residue	that	is	at	
or	below	the	concentration	deemed	safe	
for	human	consumption
The	period	necessary	between	the	last	
administration	of	the	veterinary	medicinal	
product	to	animals,	under	normal	
conditions	of	use	and	in	accordance	with	
the	provisions	of	the	Directive	2001/82/
EC,	and	the	production	of	foodstuffs	from	
such	animals,	in	order	to	protect	public	
health	by	ensuring	that	such	foodstuffs	do	
not	contain	residues	in	quantities	in	
excess	of	the	maximum	residue	limits	for	
active	substances
Legal	basis	for	HFS	
requirements
Sections	512	(d)	(1)	(A),	(B),	(D),	and	(F)	of	
the	Federal	Food,	Drug,	and	Cosmetic	
Act	(http://biotech.law.lsu.edu/blaw/
fda/fdcact5a.htm)
In	line	with	article	12.3	of	Directive	
2001/82/EC,	marketing	authorization	
applications	for	veterinary	medicinal	
products	for	use	in	food	producing	
species	must	include	an	indication	of	the	
withdrawal	period.	Article	1.9	of	the	
directive	defines	the	withdrawal	period
Guidance	
documents	
available
FDA/CVM	Guidance	for	Industry	General	
principles	for	evaluating	the	Human	
Food	Safety	of	new	animal	drugs	used	in	
food-	producing	animals	#3.	Guidance	
for	Industry—Studies	to	evaluate	the	
metabolism	and	residue	kinetics	of	
veterinary	drugs	in	food-	producing	
animals:	Marker	residue	depletion	
studies	to	establish	product	withdrawal	
periods	#207
VICH	GL48	Studies	to	evaluate	the	
metabolism	and	residue	kinetics	of	
veterinary	drugs	in	food-	producing	
animals:	Marker-	residue-	depletion	studies	
to	establish	product	withdrawal	periods	
AND	EMEA/CVMP/036/1995	Approach	
towards	harmonization	of	withdrawal	
periods
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persistence	of	 drug	 residues	 in	milk	 and	demonstrated	 the	 applica-
tion	of	NLME	for	meta-	analysis	of	data	derived	from	several	separate	
studies.	Although	 there	 are	 currently	 few	examples	 of	 pharmacoki-
netic	alterations	in	blood,	milk,	and	tissues	of	food-	producing	animals,	
there	is	an	overarching	consensus	that	the	disease	status	of	an	indi-
vidual	could	 impact	 the	disposition	kinetics	of	several	drugs,	poten-
tially	resulting	in	residue	violations	(Kissell,	Leavens,	Baynes,	Riviere,	
&	Smith,	2015;	Leavens	et	al.,	2014;	Shelver	et	al.,	2016;	Sidhu	et	al.,	
2017).	Changes	in	drug	PK	in	the	course	of	disease	progression	could	
easily	be	captured	through	NLME	analyses,	using	only	a	few	(blood,	
milk)	samples	per	individual.	Recently,	the	use	of	NLME	for	estimating	
milk	withdrawal	 time	 in	 the	European	Union	has	been	proposed	by	
scientists	from	the	French	Agency	for	Veterinary	Medicinal	Products	
(Chevance,	 Jacques,	 Laurentie,	 Sanders,	 &	 Henri,	 2017).	 Currently,	
NLME	is	not	used	by	the	US	FDA	for	the	determination	of	withdrawal	
periods	of	approved	products,	following	the	approved	label	directions.	
However,	 NLME	 would	 be	 of	 potential	 value	 for	 identifying	 those	
situations/conditions	for	which	there	may	be	a	greater	risk	of	marker	
residue	concentrations	exceeding	the	tolerance	at	 the	 labeled	with-
drawal	time.	Overall,	there	is	a	growing	interest	from	the	regulators	to	
explore	whether	or	not	NLME	could	be	used	to	assess	the	magnitude	
of	covariate-	associated	changes	in	drug	PK	susceptible	to	increase	the	
risk	of	violative	residues	in	edible	tissues.
5.2 | In companion animals
Martin-	Jimenez	 and	 Riviere	 (1998)	 published	 the	 very	 first	 NLME	
model	 applied	 to	 veterinary	 pharmacokinetics,	 using	 retrospective	
data	from	therapeutic	drug	monitoring	of	gentamicin	 in	horses.	The	
authors	 developed	 and	 validated	 a	 NLME	 model	 which	 was	 then	
used	to	design	and	adjust	clinical	doses	according	to	individual	horse	
characteristics.	Bodyweight	and	serum	creatinine	concentration	were	
found	to	explain	60%–70%	of	the	variability	in	gentamicin	PK	in	dis-
eased	horses.	In	fact,	when	interindividual	PK	variability	is	large	(as	in	
F IGURE  3 Simulated	data	for	the	tissue	residues	of	penicillin	G	in	cattle	kidney	(a),	cattle	liver	(b),	swine	kidney	(c),	and	swine	muscle	(d).	The	
99th	percentiles	of	the	simulated	penicillin	residues	are	represented	by	a	dashed	line.	The	50th	percentiles	of	the	simulated	penicillin	residues	
are	represented	by	a	dash-	dot	line.	The	observed	concentrations	(CObs)	of	the	tissue	residues	are	represented	by	closed	circles.	The	solid	lines	
are	the	tolerance	limits	of	penicillin	G	in	cattle	and	swine	tissues.	Reproduced	from	Li	et	al.	(2014)	with	permission	from	the	publisher
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this	example),	computation	of	antibiotic	doses	based	on	Monte	Carlo	
simulations,	integrating	animal	PK,	bacterial	susceptibility	distribution,	
and	target	attainment	rates,	may	result	in	under-	or	overexposure	in	
some	patients,	unless	patient	 subpopulations	have	been	adequately	
characterized.	Under	these	circumstances,	dosage	adjustments	could	
be	 recommended	on	 the	basis	 of	 various	 covariates,	 such	 as	body-
weight,	hepatic,	or	renal	function,	thereby	decreasing	the	overall	risk	
of	 underexposure	 (leading	 to	 therapeutic	 failure)	 or	 overexposure	
(raising	potential	safety	concerns)	in	some	patients.
In	1977,	Sheiner	and	co-	workers	used	NLME	to	understand	the	
factors	affecting	the	clearance	and	volume	of	distribution	of	digoxin	in	
humans	(Sheiner,	Rosenberg,	&	Marathe,	1977).	Twenty	years	later,	a	
similar	retrospective	analysis	on	the	factors	influencing	digoxin	clear-
ance	and	volume	of	distribution	in	dogs	was	presented	by	Whittem,	
Hogan,	Sisson,	and	Cooper	 (2000).	Similar	to	humans,	serum	creati-
nine	concentration	was	found	to	explain	some	of	the	PK	variability	of	
digoxin	in	dogs.	However,	an	original	finding	in	dogs	was	that	serum	
potassium	concentration	was	also	a	critical	variable	in	the	prediction	
of	digoxin	volume	of	distribution.	The	use	of	NLME	modeling	also	led	
to	the	identification	of	two	distinct	canine	subpopulations,	with	a	ten-
fold	difference	in	their	respective	absorption	rates	of	digoxin.	At	the	
time,	 the	authors	hypothesized	that	oral	dosing	of	dogs	 in	 teaching	
hospitals	vs.	at	home	caused	the	marked	delay	in	digoxin	absorption	
through	 known	 physiological	 impact	 of	 stress	 on	 gastric	 emptying.	
This	has	 recently	been	confirmed	 in	a	study	by	Warrit	et	al.	 (2017),	
which	 showed	 that	 the	 gastric	 emptying	 time	 of	 hospitalized	 dogs	
(median:	71.8	hr)	was	significantly	 longer	than	that	of	dogs	at	home	
(median:	17.6	hr).
Lately,	 NLME	models	 have	 been	 applied	 to	 several	 therapeutic	
indications	 in	 companion	 animal	 species,	 including	 cardiovascular	
disease	and	pain.	For	example,	Mochel,	Fink	et	al.	(2013)	and	Mochel	
et	al.	(2014,	2015)	studied	the	chronobiology	of	the	renin–angiotensin	
aldosterone	system	 (RAAS),	blood	pressure,	and	urinary	electrolytes	
in	dogs	to	characterize	the	optimum	time	of	dosing	with	angiotensin-	
converting	enzyme	 inhibitors	 (ACEIs).	 In	 their	mathematical	descrip-
tion	 of	 the	 RAAS,	 NLME	 was	 used	 as	 a	 tool	 for	 utilizing	 densely	
sampled	 plasma	 variables	 (i.e.,	 renin	 activity)	 to	 improve	 parameter	
estimation	 of	 (sparse)	 urinary	 endpoints.	 Subsequently,	 the	 authors	
developed	 a	 mechanism-	based	 PK/PD	 NLME	 model	 that	 captured	
the	disposition	kinetics	of	the	ACEI	benazeprilat,	and	the	time-	varying	
changes	of	systemic	RAAS	biomarkers,	without	and	with	ACE	inhibi-
tion	therapy.	Based	on	their	results,	the	optimal	efficacy	of	ACE	inhib-
itors	is	expected	with	evening	dosing	in	dogs,	which	is	consistent	with	
earlier	observations	in	humans	(Kuroda	et	al.,	2004).	Their	data	further	
showed	that	benazepril	had	a	significant	 impact	on	the	dynamics	of	
the	renin–angiotensin	cascade,	resulting	in	a	profound	decrease	in	an-
giotensin	II	(AII)	and	aldosterone	(ALD)	while	increasing	renin	activity	
for	about	24	hr.	Extrapolating	these	results	to	recent	investigations	in	
humans	 (Guder	et	al.,	2007),	 it	 is	hypothesized	that	the	reduction	 in	
AII	and	ALD	is	one	of	the	drivers	of	increased	survival	and	improved	
quality	of	life	in	dogs	receiving	ACEI	therapy.
Another	 therapeutic	 indication	 where	 NLME	 has	 been	 used	
for	 dose	 selection	 and	 covariate	 identification	 of	 NSAIDs	 in	
companion	animals	is	osteoarthritis	(OA)	(Cox	et	al.,	2011;	Fink	et	al.,	
2013;	Pelligand	et	al.,	2016;	Silber	et	al.,	2010).
The	original	analysis	by	Silber	et	al.	(2010)	showed	that	robenacoxib	
blood	 clearance	was	75%	higher	 in	 healthy	 dogs	 compared	with	OA	
patients.	Synovial	fluid	concentrations	were	modeled	using	an	effect-	
compartment-	type	approach	predicting	 longer	 residence	 times	 in	OA	
dogs	 compared	 to	 healthy	 Beagles	 (e.g.,	 concentrations	 remaining	
above	the	IC50	of	COX-	2	for	16	hr	vs.	10	hr	in	OA	and	healthy	dogs,	re-
spectively),	supporting	the	recommended	1–2	mg/kg	once-	a-	day	dos-
ing	of	robenacoxib	in	OA	dogs.	This	dosing	frequency	contributed	to	the	
favorable	safety	index	of	robenacoxib	in	field	trials.	Further	to	this	work,	
and	using	a	NLME	modeling	approach	combining	data	from	three	pro-
spective,	multicenter	field	studies	in	208	osteoarthritic	dogs,	Fink	et	al.	
(2013)	 showed	 that	 neither	 sex,	 age,	 breed,	 kidney,	 or	 liver	 function	
significantly	 influenced	 robenacoxib	PK,	 ruling	out	 the	need	 for	dose	
adjustments	based	on	these	covariates.	Finally,	Pelligand	et	al.	 (2016)	
used	NLME	to	characterize	feline	robenacoxib	disposition	kinetics	in	83	
cats,	pooling	data	from	across	seven	preclinical	(laboratory)	studies	and	
one	field	(client-	owned	cats,	perioperative	sampling)	study,	in	order	to	
evaluate	the	effect	of	anesthesia	on	robenacoxib	PK.	Using	individual	
parameter	estimates,	robenacoxib	concentration	vs	time	profiles	were	
generated	 to	determine	 the	 time	 interval	 during	which	plasma	 levels	
remained	above	a	target	PD	threshold,	for	example,	IC80	COX2	and	IC20 
COX1	 for	efficacy	and	safety	assessment,	 respectively.	This	exposure	
index	will	be	further	used	as	a	covariate	to	support	the	perioperative	
clinical	efficacy	and	safety	evaluation	of	robenacoxib	in	cats.
For	mavacoxib,	simulations	from	a	NLME	PK	model	showed	that	a	
2	mg/kg	dose	was	sufficient	to	maintain	trough	concentrations	above	
a	 threshold	efficacy	 level	 in	dogs.	These	 results	were	key	 to	 reduce	
the	 recommended	dose	of	mavacoxib	 from	4	 to	2	mg/kg,	which	ul-
timately	 increased	 the	 therapeutic	 index	of	mavacoxib	 in	dogs	 (Cox	
et	al.,	2011).
6  | SPECIFIC CHALLENGES TO 
VETERINARY MEDICINE
6.1 | Data analysis of sparse and/or unbalanced data 
in limited sample sizes
In	human	medicine	and	during	development	of	a	new	chemical	entity,	
phase	III	PK	studies	typically	involve	a	large	number	of	subjects	and	
oftentimes	(Rubino,	Bhavnani,	Moeck,	Bellibas,	&	Ambrose,	2015),	but	
not	 always	 (Desai	 et	al.,	 2016),	 contain	patient	data	derived	 from	a	
sparse	sampling	schedule.	In	veterinary	medicine,	similarly	large	stud-
ies	are	uncommon	often	due	to	economic	and	practical	constraints.
When	using	sparse	data,	accurate	and	precise	estimation	of	PK	pa-
rameters	and	their	variability	is	heavily	dependent	on	the	experimental	
design	 (Ette,	Williams,	&	Lane,	2004).	As	the	sample	size	decreases,	
so	does	the	ability	to	properly	estimate	model	parameters.	Therefore,	
when	the	sample	size	of	a	PK	experiment	is	expected	to	be	relatively	
low	(as	is	often	the	case	in	veterinary	medicine),	one	needs	to	carefully	
consider	the	design	of	the	experimental	protocol	(Jones,	Sun,	&	Ette,	
1996;	Jonsson,	Wade,	&	Karlsson,	1996).	Among	relevant	factors	are	
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(i)	the	sampling	times,	(ii)	a	priori	knowledge	about	the	expected	vari-
ability	and	(iii)	the	underlying	PK	model	structure.	For	instance,	when	
a	one-	compartment	model	is	used	to	describe	the	PK	of	a	drug	admin-
istered	intravenously	(IV),	the	best	sampling	times	are	those	early	time	
points	 after	dose	administration,	 and	 the	 late	 time	points	when	 the	
concentrations	are	close	(but	above)	the	lower	limit	of	quantification	
(Endrenyi,	1981;	Ette,	Howie,	Kelman,	&	Whiting,	1995).
The	relatively	short	period	of	time	during	which	veterinary	patients	
are	available	for	sampling,	and	the	limited	number	of	samples	that	can	
be	collected	per	animal	are	additional	factors	to	be	considered.	Under	
production	conditions,	food	animals	tend	to	be	available	for	extended	
periods	of	time,	but	the	number	of	samples	that	can	be	collected	from	
each	animal	varies	depending	on	the	animal	size,	restraining	measures	
available,	and	the	health	status	of	the	animal.	For	small	animals,	 the	
length	of	stay	in	veterinary	hospitals,	the	animal	size,	and	other	ethical	
or	practical	issues	(e.g.,	owner	consent)	will	affect	not	only	the	number	
of	samples	that	can	be	collected	per	animal,	but	also	the	timing	of	sam-
ple	collections.	 In	practice,	gathering	 information	about	the	terminal	
phase	of	the	PK	profile	will	often	be	contingent	upon	the	feasibility	of	
hospitalizing	the	animal	for	more	than	a	couple	of	hours	after	dosing.
In	 light	 of	 these	 challenges,	 the	 incorporation	 of	 optimum	 sam-
pling	strategies	in	the	study	design	is	critical.	In	theory,	samples	should	
be	obtained	at	those	times	when	the	information	on	relevant	PK	pa-
rameters	 is	 maximal.	 In	 fact,	 Sheiner	 and	 Beal	 (1983)	 showed	 that	 
parameters	are	estimated	with	increased	accuracy	when	the	number	
of	subjects	increases,	but	that	increasing	the	number	of	samples	does	
not	improve	parameters	estimation	if	the	drug	is	administered	IV	and	
exhibits	a	mono-	exponential	decline.	Likewise,	Al-	Banna,	Kelman,	and	
Whiting	(1990)	used	Monte	Carlo	simulation	to	compare	several	sam-
pling	strategies	in	50	subjects	for	a	test	drug	with	one-	compartment	
IV	 kinetics.	Acceptable	 results	were	obtained	with	 two	 samples	 per	
individual	collected	at	random	times,	but	improved	precision	and	ac-
curacy	in	the	estimation	of	clearance	was	observed	when	the	second	
sample	was	collected	at	 later	time	points.	 In	this	analysis,	 increasing	
the	number	of	subjects	or	the	sampling	frequency	did	not	significantly	
improve	 the	 estimation	 of	 the	model	 fixed	 effects,	 but	 significantly	
increased	 that	 of	 the	 random	effects.	This	was	 later	 confirmed	 in	 a	
study	by	Ette,	Sun,	and	Ludden	(1998).	More	recently,	Lee	(2001)	used	
Monte	Carlo	 simulations	 to	assess	 the	effect	of	 sampling	 schedules	
on	the	ability	to	identify	a	subpopulation	with	a	30%	higher	clearance	
than	the	average	individual.	Although	increasing	the	number	of	sub-
jects	from	100	to	200	had	little	effect	on	the	power	of	the	test,	the	
frequency	and	 sampling	 times	appeared	 to	be	critical	 to	detect	 this	
patient	subpopulation.
Translating	these	published	simulations	to	real-	life	situations	need	
to	 be	 tempered	 by	 an	 appreciation	 of	 the	 simplistic	 premise	 upon	
which	they	are	based.	In	many	instances,	an	IV	formulation	was	used	
for	generating	the	PK	model	 in	early	preclinical	studies.	However,	 in	
the	 clinic,	 there	 are	 few	marketed	 veterinary	 formulations	 that	 are	
approved	 for	use	 as	 an	 IV	 injection.	Rather,	 alternative	 routes	 (sub-
cutaneous	or	intramuscular	injections,	oral	formulations,	transdermal	
systems)	are	associated	with	an	absorption	component	that	may	con-
found	the	shape	of	the	profile	observed	following	drug	administration	
via	IV	injection.	One	advantage	of	NLME	models	is	that	data	from	var-
ious	sources,	including	IV	experiments	from	early	research	and	clinical	
extravascular	studies,	can	be	pooled	together	to	allow	the	estimation	
of	PK	model	parameters.	The	experimental	design	used	to	capture	the	
individual	variations	in	the	absorption,	distribution(s),	and	elimination	
phases	needs	to	be	considered	when	gathering	the	data	used	for	char-
acterizing	PK	variability	across	a	patient	population.	Examples	of	ap-
proaches	that	have	been	used	for	characterizing	population	variability	
in	PK	include	the	use	of	an	adaptive	rather	than	a	fixed	study	design	
(Drusano,	Forrest,	Snyder,	Reed,	&	Blumer,	1988);	the	MAP-	Bayesian	
(nonparametric)	approach	(Kashuba,	Ballow,	&	Forrest,	1996),	or	the	
population	bridging	approach	as	discussed	by	Foo	and	Duffull	(2012).	
Such	methods	involve	interim	analysis	and	fine-	tuning	of	the	design	as	
subjects	are	accrued.	Note	that,	from	the	perspective	of	the	conditions	
under	which	the	data	will	be	gathered,	it	may	be	more	appropriate	to	
randomize	individuals	with	respect	to	a	time	window	rather	than	a	rig-
idly	constrained	set	of	time	points	(Graham	&	Aarons,	2006).
6.2 | The input dose as a random variable
In	collective	therapy,	the	input	dose	can	be	greatly	influenced	by	social	
hierarchy,	as	for	instance	reported	in	pigs	after	oral	administration	of	
fosfomycin	(Soraci	et	al.,	2014).	In	this	study,	variations	in	fosfomycin	
PK	were	largely	explained	by	differences	in	feeding	behavior,	result-
ing	 in	varying	 ingested	amounts	of	drug	between	animals.	Although	
several	workarounds	are	described	in	the	literature,	the	approach	of	
Li	and	Nekka	(2007),	which	consists	of	formally	including	a	stochastic	
drug	input	function	in	the	PK	model,	seems	particularly	relevant.	An	
alternative	is	to	model	the	nominal	dose	as	an	independent	variable	
and	 introduce	a	random	effect	on	oral	bioavailability	 to	account	 for	
the	variability	in	drug	intake	between	individuals.	Part	of	this	variabil-
ity	can	then	be	explained	by	specific	covariates	such	as	social	hierar-
chy	and	husbandry	practices	 (e.g.,	pen	size).	Future	directions	 in	pig	
production	will	allow	individualization	of	dosing	through	RFID	(radi-
ofrequency	 identification)	 technology.	Under	 the	NLME	framework,	
covariates	of	interest	(e.g.,	sex	and	bodyweight)	could	be	used	to	in-
dividualize	dosing	schedules.	Also,	by	monitoring	water	consumption	
via	RFID	(a	fingerprint	of	early	disease	in	pigs),	one	should	be	able	to	
selectively	treat	diseased	animals,	which	is	the	next	step	forward	to	
the	stewardship	use	of	antimicrobials	in	livestock	production	systems	
(Ferran,	Toutain,	&	Bousquet-	Melou,	2011;	Vasseur	et	al.,	2014).
7  | REGULATORY ISSUES 
AND ACCEPTANCE
The	 regulatory	 requirements	 that	 can	be	 instituted	by	 the	FDA	are	
constrained	 by	 the	 existing	 laws	 that	 govern	 the	 activities	 of	 the	
Agency.	 Unlike	 that	 encountered	 in	 human	 medicine	 (FDA/CVM,	
2016),	there	is	no	statutory	requirement	for	PK	data	to	be	provided	in	
support	of	the	approval	of	an	animal	drug	application.	Accordingly,	al-
though	the	FDA	reviewer	may	share	perspectives	with	drug	sponsors	
with	 respect	 to	 the	 potential	 benefits	 of	 collecting	 PK	 information,	
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the	FDA	typically	cannot	legally	require	sponsors	to	collect	PK	data	in	
support	of	their	new	animal	drug	application.	In	other	words,	there	is	
no	requirement	for	sponsors	to	provide	a	description	of	the	popula-
tion	PK	variability	 that	 is	expected	when	the	product	 is	used	 in	the	
targeted	 animal	 patient	 population.	 The	 absence	 of	 regulatory	 re-
quirement	does	not,	however,	prohibit	a	drug	sponsor	from	submit-
ting	such	information	to	support	product	development,	or	to	provide	
a	basic	foundation	of	 information	that	can	address	regulatory	ques-
tions	that	may	arise	over	the	pre-	and	postapproval	life	of	a	product.	
An	example	of	this	is	embodied	in	the	recently	published	CVM	guid-
ance	on	parenteral	dosage	forms	(FDA/CVM,	2016),	which	contains	a	
section	on	how	to	establish	in	vitro–in	vivo	correlations	for	address-
ing	 formulation	 and	manufacturing	 questions	 that	 can	occur	 during	
product	development,	and	as	a	consequence	of	postapproval	product	
modifications.
In	 the	 EU,	 the	 situation	 is	 different.	 The	 last	 Committee	 for	
Medicinal	 Products	 for	 Veterinary	 Use	 (CVMP)	 guideline	 for	 the	
demonstration	of	efficacy	for	veterinary	medicinal	products	containing	
antimicrobial	substances	explicitly	mentions:
For group/flock medication via water or feed, the variabil-
ity between animals in feed/water intake should be ex-
plored through appropriate sampling of the animals, with 
the purpose of ensuring that the dose selected will provide 
therapeutic exposure levels in all animals. In addition, pop-
ulation PK/PD models (such as Monte Carlo simulations) 
based on data from field trials could be used to bring sup-
port for a post- hoc analysis of the selected dose.
This	is	in	line	with	the	CVMP	Concept	paper	for	the	current	revision	
on	 the	guideline	 for	 the	conduct	of	pharmacokinetic	 studies	 in	 target	
animal	species	(EMEA/CVMP/133/99-	Final).
Irrespective	 of	whether	 or	 not	 PK	 data	 are	 a	 necessary	 compo-
nent	of	a	regulatory	application,	the	systemic	availability	of	a	parent	
compound	and	its	metabolites	can	influence	drug	product	safety	and	
effectiveness.	As	such,	disposition	kinetic	data	can	affect	the	design	
and	interpretation	of	clinical	trials,	the	extrapolation	of	target	animal	
safety	results	to	the	intended	animal	patient	population,	or	the	assess-
ment	of	postmarketing	adverse	event	reports.	Therefore,	although	not	
required	by	the	US	FDA,	PK	information	is	an	invaluable	component	of	
product	development	in	veterinary	medicine.
8  | CONCLUSIONS
This	 review	 emphasizes	 the	 need	 for	 a	 concerted	 effort	within	 the	
animal	 health	 community	 to	 enhance	 awareness	 and	 understand-
ing	 of	 the	 potential	 applications	 of	 NLME	 in	 veterinary	 medicine.	
Identification	 of	 the	 key	 population	 characteristics	 that	 drive	 vari-
ability	 in	 the	drug	PK	between	 animals	 is	 essential	 to	 the	 selection	
of	 a	 rational	 dosing	 strategy.	 This	 has	 broad	 implications	 to	 ensure	
optimum	efficacy	and	safety	of	therapeutics	in	both	companion	and	
food-	producing	animals.	However,	caution	must	be	exercised	both	in	
the	execution	and	interpretation	of	these	models.	Equally	critical	are	
the	 statistical	 and	 sample	 (study	 design)	 assumptions	 within	 which	
these	studies	are	analyzed.	Hopefully,	as	veterinary	pharmacologists	
appreciate	the	strength	and	efficiency	of	these	tools,	there	will	be	an	
increase	in	the	use	of	modeling	and	simulation	approaches	to	support	
the	future	of	animal	health.
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